Connecticut Academy of Family Physicians’ Post

Featured Research article from our latest JFMB 2nd issue Vol.66 concludes that: ATPase and GTPase levels are increased in patients with fibrotic lung disease regardless of the COVID-19 vaccination state.  https://lnkd.in/eXht7VDZ

Featured Research article from our latest JFMB 2nd issue Vol.66 concludes that: ATPase and GTPase levels are increased in patients with fibrotic lung disease regardless of the COVID-19 vaccination state.  https://lnkd.in/exwueyZZ

Happy to share the results of this noteworthy meta-analysis on the efficacy or RSV vaccination in preventing lower respiratory tract illnesses in older adults A "hot" topic for Internal Medicine Physicians due to the extreme frequency of lower respiratory tract infections in our Units. A special thank to Dr Giuri (a coauthor of the paper) that reported this important paper to me. Full text is available at: https://lnkd.in/dCz_gB-J #lowerrespiratorytractinfection #rsv #vaccine

New report alert! 📢 We've collaborated with Bamberg Health and Asociación Española de Vacunología on a new report that highlights the need for adult vaccination strategies across Europe. Our findings underscore how life-course immunisation can reduce disease burden, lower healthcare costs, and promote economic stability. From Spain's RSV advancements to dedicated vaccine funding, this report points to critical steps for building a resilient healthcare model. Read more about our work here: 🔗 https://lnkd.in/ebfHJUit and share your thoughts on how Europe can prioritize prevention! 🌟💉 #PublicHealth #Immunisation #HealthcareInnovation #PreventiveCare #HealthyEurope

📊 Don’t miss our recent report on adult vaccination strategies in Europe! It underscores the essential role of life-course immunisation in enhancing public health outcomes. Explore the key insights and recommendations here: 🔗https://lnkd.in/ep_X4SGQ

Did you know? Spain is leading the way by becoming one of the first countries to introduce RSV immunisation with Nirsevimab for infants, showcasing the potential of proactive vaccination strategies. 💡 This proves that proactive vaccination policies work — but why aren’t they adopted widely? Across Europe, low vaccine budgets hinder progress, with most countries investing less than 0.5% of healthcare funds in immunisation. 📊 Discover how Spain's approach can inspire life-course immunisation across the region. Read the full report ⬇️

Life-course immunisation plays a crucial role in reducing disease burden, lowering healthcare costs, and promoting economic stability. 📉💉 Discover the key steps needed to build a resilient healthcare model in this insightful report, produced in collaboration with our client. 📊🏥

Powerful Danish study presented @EICA by Dr Biering-Sorensen reveals the impact of letter interventions in increasing influenza vaccination rates among older adults with and without CVD, showcasing potential cardiovascular benefits. Published in Eur Heart J, 2024 the study's findings shed light on the efficacy of such interventions. #DanishStudy #InfluenzaVaccination #CardiovascularBenefits

The respiratory syncytial virus (RSV) vaccine is recommended for immunocompromised individuals aged 60 and above despite limited data. In an electronic health records-based observational study that included over 10,000 predominantly mild to moderately immunocompromised individuals ≥60 year olds, vaccine effectiveness was 73 percent against RSV-associated hospitalization at follow-up of one year. This study supports vaccination against RSV in immunocompromised individuals aged 60 and above. Stay #UpToDate with What's New in #InfectiousDiseases: https://ow.ly/VsNM50UebZr #ClinicalUpdates #meded

Meet the Experts Who Steer US Vaccine Policy By Damian Garde Hello, everyone. Damian in Miami here with a look at a little-discussed group with outsized influence on US public health. Meet the experts behind US vaccine policy If you’re in the US, you’re probably used to seeing seasonal headlines about who should get what vaccine. You know, guidance like that people over 60 should get an RSV shot or that some people need more Covid boosters. And you might have wondered: Says who? The answer is the US Centers for Disease Control and Prevention. But more specifically, that responsibility falls on a sort of public health all-star team tasked with kicking the tires on every new vaccine to determine whether it’s worth the hassle — and the cost — of rolling out nationwide. It’s called the Advisory Committee on Immunization Practices, or ACIP, and it’s made up of 15 independent experts who gather in Atlanta three times a year for a rubber-meets-road debate about vaccines. The process starts at the US Food and Drug Administration, which approves new vaccines based on whether they’ve proved to be safe and effective. Then it’s ACIP’s job to take the conversation further. A new vaccine might work in a clinical trial, but can it be practically administered in, say, a rural pediatrician’s office? And, with the CDC spending hundreds of millions of dollars a year to subsidize immunizations, can it do enough good to justify taxpayers shelling out for it? ACIP members hash all that out in their public meetings. Last week, for example, ACIP spent hours digging into a new Merck vaccine for a bacterial infection that causes pneumonia. Then they issue an opinion to the head of the CDC, who typically makes their findings an official recommendation. And then you get the headlines about Covid-19 boosters, flu shots, and RSV vaccines. “It’s a very healthy part of the scientific process,” says Katherine Poehling, a Wake Forest University pediatrician and former ACIP member. Applicants to the panel are screened for conflicts of interest, and every shred of data they discuss is uploaded to the CDC’s website where anyone can find it, alongside the YouTube livestream of their meetings. Continued.....Please click on image in the banner below to access and finish reading this article. Posted by Larry Cole